SNSE Stock Overview
An immuno-oncology company, engages in the discovery and development of therapeutics for cancer patients.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
Sensei Biotherapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.36 |
| 52 Week High | US$1.94 |
| 52 Week Low | US$0.51 |
| Beta | 0.14 |
| 1 Month Change | 46.10% |
| 3 Month Change | 80.11% |
| 1 Year Change | -15.53% |
| 3 Year Change | -89.02% |
| 5 Year Change | n/a |
| Change since IPO | -92.80% |
Recent News & Updates
Recent updates
Is Sensei Biotherapeutics (NASDAQ:SNSE) In A Good Position To Deliver On Growth Plans?
Nov 03
We Think Sensei Biotherapeutics (NASDAQ:SNSE) Needs To Drive Business Growth Carefully
Jul 02Here's Why We're Watching Sensei Biotherapeutics' (NASDAQ:SNSE) Cash Burn Situation
Mar 14We're Hopeful That Sensei Biotherapeutics (NASDAQ:SNSE) Will Use Its Cash Wisely
Aug 14Sensei Biotherapeutics GAAP EPS of -$0.34 beats by $0.06
Aug 09Here's Why We're Watching Sensei Biotherapeutics' (NASDAQ:SNSE) Cash Burn Situation
Apr 18Sensei Biotherapeutics (NASDAQ:SNSE) Is In A Good Position To Deliver On Growth Plans
Nov 16Shareholder Returns
| SNSE | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -8.7% | 0.07% | -0.2% |
| 1Y | -15.5% | 6.9% | 28.2% |
Return vs Industry: SNSE underperformed the US Biotechs industry which returned 5% over the past year.
Return vs Market: SNSE underperformed the US Market which returned 27.7% over the past year.
Price Volatility
| SNSE volatility | |
|---|---|
| SNSE Average Weekly Movement | 15.1% |
| Biotechs Industry Average Movement | 11.3% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in US Market | 16.0% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: SNSE's share price has been volatile over the past 3 months.
Volatility Over Time: SNSE's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 28 | John Celebi | www.senseibio.com |
Sensei Biotherapeutics, Inc., an immuno-oncology company, engages in the discovery and development of therapeutics for cancer patients. The company’s Tumor Microenvironment Activated Biologics platform is designed to generate highly selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. It also offers SNS-101, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune checkpoint VISTA for the treatment of solid tumors.
Sensei Biotherapeutics, Inc. Fundamentals Summary
| SNSE fundamental statistics | |
|---|---|
| Market cap | US$35.11m |
| Earnings (TTM) | -US$31.92m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-1.1x
P/E RatioIs SNSE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SNSE income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$31.92m |
| Earnings | -US$31.92m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.27 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did SNSE perform over the long term?
See historical performance and comparison